Key facts
- This page summarizes Renee D. Gala's Form 4 filing for Gossamer Bio, Inc. (GOSS).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 09 Jun 2023, 16:15.
Renee D. Gala - 08 Jun 2023 Form 4 Insider Report for Gossamer Bio, Inc. (GOSS)
- Reporting relationship
- Director
- Issuer ticker
- GOSS
- Reported as of
- 08 Jun 2023
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 09 Jun 2023, 16:15:57 UTC
- Prior SEC filing
- 19 May 2023
- Next SEC filing
- 14 Nov 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Jeff Boerneke, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Renee D. Gala filed Form 4 for Gossamer Bio, Inc. (GOSS) on 09 Jun 2023.
Change
- Previous filing in this sequence was filed on 19 May 2023.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
GOSS
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +35,000
- Change %
- Price
- $0.000000
- Shares after
- 35,000
- Date
- 08 Jun 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 35,000
- Exercise price
- $1.26
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Award made pursuant to Non-Employee Director Compensation Program.
Footnote F2
The entire number of shares subject to this option becomes fully vested and exercisable on the first to occur of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date.